The Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease According to Polysystemic Ultrasound of the Arteries and Hepatic Steatometry

  • O. B. Dynnyk Medical center “Institute of elastography”, Kyiv, Ukraine
  • S. E. Mostovy Medical center “Doctor Vera”, Kyiv, Ukraine
  • G. L. Boyko National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute”, Kyiv, Ukraine
  • E. A. Nastenko National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute”, Kyiv, Ukraine; National Amosov Institute of Cardiovascular Surgery, Kyiv, Ukraine
  • N. G. Gnoeva National Amosov Institute of Cardiovascular Surgery, Kyiv, Ukraine
Keywords: atherosclerosis, non-alcoholic fatty liver disease, polysystemic ultrasound, intima-media complex, liver steatometry


Introduction. Coronary heart disease (CHD) remains the most common cause of death and disability in Ukraine and around the world. CHD is caused by atherosclerosis. Non-alcoholic fatty liver disease (NAFLD) is considered an independent predictor of CHD.

Aim. To identify the relationship between atherosclerosis and NAFLD according to polysystemic ultrasound (ps-US) of the arteries and liver steatometry.

Materials and methods. We conducted an open prospective study in 2019 of 93 people, including 58 women and 35 men aged 22 to 79 years. Chronic CHD was detected in 36 patients and 57 apparently healthy individuals. US was performed by Soneus P7 (Ultrasign, Ukraine). We determined condition of the abdominal organs in the B-mode as well as the amount extent of hepatic steatosis – through steatometry by attenuation coefficient (AC) measurement – ACM) for the diagnosis of NAFLD. Atherosclerosis of the abdominal aorta and common carotid arteries (atherosclerotic plaques and the thickness of the intima-media complex) was detected.

Results and discussion. There was an increase in AC (a sign of NAFLD) in 36 patients with CHD. The presence of carotid atherosclerosis confirms a higher percentage of patients with signs of hepatosis in the CHD group.

Conclusions. An innovative method of quantitative ultrasound of hepatosteatosis (steatometry) can be used as a screening for the detection of NAFLD in population studies. The relationship between markers of atherosclerosis and NAFLD has been revealed according to the data of ps-US of the arteries and hepatic steatometry which allows to prescribe comprehensive treatment and evaluate its effectiveness. NAFLD can be a predictor of atherosclerosis and the formation of CHD, which gives grounds for the primary prevention of the latter.


  1. Nambi V, Chambless L, He M, Folsom AR, Mosley T, Boerwinkle E, Ballantyne CM. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. European Heart Journal. 2012;33(2):183-90.
  2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016;64(6):1388-402.
  3. Kapuria D, Takyar VK, Etzion O, Surana P, O’Keefe JH, Koh C. Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta‐analysis. Hepatology Communications. 2018;2(8):873-83.
  4. Zhou Y-Y, Zhou X-D, Wu S-J, Fan D-H, Van Poucke S, Chen Y-P, Fu S-W, Zheng M-H. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatology Communications. 2018;2(4):376-92.
  5. Кейян ВА, Сандлер ЮГ, Хайменова ТЮ, Хомерики СГ, Никаноров АВ, Салиев КГ, Винницкая ЕВ. Диагностическая значимость стеатометрии при хронических заболеваниях печени. Эффективная фармакотерапия. 2020;16(1):40-4.
  6. Kejan VA, Sandler YuG, Khaimenova TYu, Khomeriki SG, Nikanorov AV, Saliev KG, Vinnickaya EV. [Diagnostic value of steatometry in chronic liver diseases]. Effective Pharmacotherapy. 2020;16(1):40-4. Russian.
  7. VanWagnerLB,WilcoxJE,NingH,LewisCE,CarrJJ,RinellaME, Shah SJ, Lima JA, Lloyd-Jones DM. Longitudinal association of non‐alcoholic fatty liver disease with changes in myocardial structure and function: The CARDIA Study. Journal of the American Heart Association. 2020;9(4):e014279.
  8. Дынник ОБ, Федусенко АА, Кобыляк НН, Линская АВ. 6 измерений ультразвуковой диагностики диффузных заболеваний печени или мультипараметрический ультразвук. Променева діагностика, променева терапія. 2016;3-4:69-84.
  9. Dynnik OB, Fedusenko AA, Kobilyak NN, Linskaya AV. [6 Measurements Ultrasonography of Diffuse Liver Disease or Multiparametric Ultrasound]. Promeneva diahnostyka, promeneva terapiia. 2016;3-4:69-84. Russian.
  10. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36(1):13-20.
  11. Кособян ЕП, Смирнова ОМ. Современные концепции патогенеза неалкогольной жировой болезни печени. Сахарный диабет. 2010;(1):55-64.
  12. Kosobyan EP, Smirnova OM. [Current concepts of the pathogenesis of non-alcoholic fatty liver disease]. Diabetes mellitus.2010;(1):55-64. Russian.
  13. Zhang L, Guo K, Lu J, Zhao F, Yu H, Han J, Bao Y, Chen H,Jia W. Nonalcoholic fatty liver disease is associated with increased carotid intima-media thickness in type 1 diabetic patients. Scientific reports. 2016;6:26805.
  14. Guo Y-C, Zhou Y, Gao X, Yao Y, Geng B, Cui Q-H, Yang J-C, Hu Y-P. Association between nonalcoholic fatty liver disease and carotid artery disease in a community-based Chinese population: a cross-sectional study. Chinese Medical Journal. 2018;131(19):2269-76.
  15. Misra VL, Khashab M, Chalasani N. Non-alcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11(1):50-5.
  16. Al Rifai M, Silverman MG, Nasir K, Budoff MJ, Blankstein R, Szklo M, Katz R, Blumentha RS, Blaha MJ. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2015;239(2):629-33.
  17. Choudhary NS, Duseja A. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? Journal of Clinical and Experimental Hepatology. 2019;9(4):506-14.
  18. Polak JF, O’Leary DH. Carotid intima-media thickness as surrogate for and predictor of CVD. Global Heart. 2016;11(3):295-312.e3.
How to Cite
Dynnyk, O. B., Mostovy, S. E., Boyko, G. L., Nastenko, E. A., & Gnoeva, N. G. (2020). The Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease According to Polysystemic Ultrasound of the Arteries and Hepatic Steatometry. Ukrainian Journal of Cardiovascular Surgery, (3 (40), 88-92.